OBJECTIVE: To investigate the role of oral ivabradine as a heart rate reducing agent in patients undergoing CT coronary angiography (CTCA). Despite the routine use of β-blockers prior to CTCA studies, it is not uncommon to have patients with heart rates persistently above the target range of 65 bpm. Ivabradine is a selective inhibitor of the I(f) current, which primarily contributes to sinus node pacemaker activity, and has no significant direct cardiovascular effects such as reduction of blood pressure, cardiac contractility or impairment of cardiac conduction. METHODS: We investigated 100 consecutive patients who had been referred for CTCA for the evaluation of suspected coronary artery disease (CAD). Patients were randomised to receive either of the following two pre-medication protocols: oral metorprolol or oral ivabradine. RESULTS:Ivabradine was significantly more effective than metorprolol in lowering the heart rate; the mean percentage reduction in heart rate with ivabradine vs metorpolol was 23.89+6.95% vs 15.20+4.50%, respectively (p=0.0001). Metoprolol significantly lowered both systolic and diastolic blood pressure while ivabradine did not. The requirement of additional doses to achieve a target heart rate of <65 beats per min was also significantly more frequent with metoprolol. CONCLUSION:Ivabradine is a potentially attractive alternative to currently used drugs for reduction of heart rate in patients undergoing CTCA.
RCT Entities:
OBJECTIVE: To investigate the role of oral ivabradine as a heart rate reducing agent in patients undergoing CT coronary angiography (CTCA). Despite the routine use of β-blockers prior to CTCA studies, it is not uncommon to have patients with heart rates persistently above the target range of 65 bpm. Ivabradine is a selective inhibitor of the I(f) current, which primarily contributes to sinus node pacemaker activity, and has no significant direct cardiovascular effects such as reduction of blood pressure, cardiac contractility or impairment of cardiac conduction. METHODS: We investigated 100 consecutive patients who had been referred for CTCA for the evaluation of suspected coronary artery disease (CAD). Patients were randomised to receive either of the following two pre-medication protocols: oral metorprolol or oral ivabradine. RESULTS:Ivabradine was significantly more effective than metorprolol in lowering the heart rate; the mean percentage reduction in heart rate with ivabradine vs metorpolol was 23.89+6.95% vs 15.20+4.50%, respectively (p=0.0001). Metoprolol significantly lowered both systolic and diastolic blood pressure while ivabradine did not. The requirement of additional doses to achieve a target heart rate of <65 beats per min was also significantly more frequent with metoprolol. CONCLUSION:Ivabradine is a potentially attractive alternative to currently used drugs for reduction of heart rate in patients undergoing CTCA.
Authors: Jaap M Groen; Marcel J W Greuter; Peter M A van Ooijen; Tineke P Willems; Matthijs Oudkerk Journal: J Comput Assist Tomogr Date: 2006 Sep-Oct Impact factor: 1.826
Authors: Stephen Schroeder; Andreas F Kopp; Axel Kuettner; Christof Burgstahler; Christian Herdeg; Martin Heuschmid; Andreas Baumbach; Claus D Claussen; Karl R Karsch; Ludger Seipel Journal: Clin Imaging Date: 2002 Mar-Apr Impact factor: 1.605
Authors: Tom Giesler; Ulrich Baum; Dieter Ropers; Stefan Ulzheimer; Evelyn Wenkel; Maria Mennicke; Werner Bautz; Willi A Kalender; Werner G Daniel; Stephan Achenbach Journal: AJR Am J Roentgenol Date: 2002-10 Impact factor: 3.959
Authors: Paul Mulder; Stephane Barbier; Abdeslam Chagraoui; Vincent Richard; Jean Paul Henry; Françoise Lallemand; Sylvanie Renet; Guy Lerebours; Florence Mahlberg-Gaudin; Christian Thuillez Journal: Circulation Date: 2004-02-23 Impact factor: 29.690
Authors: Viktoria Muster; Markus Wallner; Albrecht Schmidt; Martin Kapl; Friederike von Lewinski; Peter Rainer; Pia Reittner; Manfred Tillich; Peter Brader; Dieter Hm Szolar; Dirk von Lewinski Journal: J Int Med Res Date: 2018-04-03 Impact factor: 1.671